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Abstract: Hypertension is the most prevalent cardiovascular disease of adults and is a major 
risk factor for cardiovascular (CV) and cerebrovascular morbidity and mortality worldwide. 
  Treatment of hypertension leads to reduction of CV morbidity and mortality through blood pres-
sure reduction. The role of renin–angiotensin–aldosterone system (RAAS) in the pathophysiology 
of hypertension is mainly through generation of potent vasoconstrictor   angiotensin II, stimulation 
of aldosterone secretion, and increase in sympathetic activation. Angiotensin II receptor block-
ers such as candesartan, a long-acting agent, alter this system by blocking the activation of 
angiotensin I receptors. Several important clinical trials have tested the efficacy of candesartan 
with placebo, antihypertensive agents, or other agents that block the RAAS for the control of 
hypertension and reduction of key CV risk factors such as microalbuminuria, heart failure, 
retinopathy, and carotid intima medial thickness. Candesartan has been shown to be a well-
tolerated and effective antihypertensive agent with positive metabolic characteristics and 
additional benefits on CV and cerebrovascular outcomes. The aim of this review is to discuss 
the pharmacology, efficacy, and safety of candesartan, with an overview of key hypertension 
and CV studies involving candesartan.
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Introduction to hypertension management  
and CV risk reduction
Hypertension is the most prevalent cardiovascular disease (CVD) of adults and is 
a major risk factor for both cardiovascular (CV) and cerebrovascular morbidity 
and mortality worldwide.1 Although the results of several cross-sectional or cohort 
epidemiological studies have shown that the prevalence of hypertension varies 
significantly,2–7 essential hypertension is estimated to affect 30% of adults8,9 and to 
account for up to 30% of all deaths.1 The relationship between blood pressure (BP) 
and CV risk is continuous such that every 20 mmHg increase in systolic BP (SBP) 
or 10 mmHg increase in diastolic BP (DBP) doubles the risk of CVD.10 The main 
objective of hypertension treatment is to reduce CV morbidity and mortality by 
reducing BP.11 Inameta-analysis of placebo-controlled hypertension studies, for every 
12/6 mmHg reduction in BP, there was a 35%–40% reduction in stroke, 20%–25% 
reduction in myocardial infarction, and .50% in heart failure (HF) and prevention 
of CVD-related death rates.11
An estimated one-third of all hypertensive patients still remain untreated despite the 
level of awareness of hypertension worldwide, and over half of those treated have uncon-
trolled hypertension.12 The increased mortality and morbidity   associated with uncon-Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
46
Okpechi and Rayner
trolled hypertension results in a substantial economic burden. 
  Antihypertensives that are effective and well   tolerated are impor-
tant for persistence with therapy and hence control of BP.
The role of renin–angiotensin–aldosterone system 
(RAAS) in the pathophysiology of hypertension is pivotal 
mainly through the generation of powerful vasoconstrictor 
angiotensin II, which significantly contributes to hyperten-
sion through vasoconstriction, stimulation of aldosterone 
secretion, and increase in sympathetic activation. Angiotensin 
II receptor blockers (ARBs), therefore, modulate the RAAS 
by blocking the activation of angiotensin I (AT1) receptors, 
resulting in vasodilatation, reduced sympathetic activa-
tion, and reduced salt and water retention. ARBs also block 
  angiotensin II production irrespective of whether it is gener-
ated by AT1 through angiotensin converting enzyme (ACE)
pathway or through alternative pathways such as chymase. 
This article reviews the pharmacology, efficacy, and safety of 
candesartan (an ARB), with an overview of key hypertension 
and CV studies involving candesartan.
Pharmacology of candesartan
After oral administration, candesartan cilexetil is rapidly 
converted to candesartan (an active drug) by hydrolysis in 
the gastrointestinal tract, with an average absolute bioavail-
ability of candesartan of approximately 40%. Candesartan is 
highly bound to plasma protein (.99%).13 The serum con-
centration (AUC) of candesartan is not significantly affected 
by food intake, and Tmax is reached within 3–5 hours after 
oral administration.13 The AUC of candesartan has shown 
dose linearity with increasing doses in the therapeutic dose 
range.14 Elimination of the drug is largely via urine and bile 
in an unchanged form, and only an insignificant amount of 
the drug is inactivated by hepatic metabolism. an oral dose 
of candesartan, about 20%–30% is excreted in urine and 
60%–70% is excreted in feces. The apparent volume of dis-
tribution of candesartan is 0.1 L/kg. The terminal half-life 
of candesartan is 5–9 hours, and no significant accumulation 
after multiple doses was observed (plasma concentrations 
+3% to +17%).14 Total plasma clearance of candesartan 
is about 0.37 mL/min/kg, with a renal clearance of about 
0.19 mL/min/kg. Candesartan has high selectivity for AT1 
receptors, with tight binding to and slow dissociation from 
the receptor.15 In displacement studies using rabbit aortic 
membranes, candesartan’s affinity for the AT1 receptor was 
found to be 80 times higher than that of losartan.16 Due to 
candesartan’s tight binding to and slow dissociation from the 
AT1 receptors, candesartan cilexetil provides a dose-related 
and long-lasting antihypertensive effect.15,17
Candesartan: antihypertensive 
efficacy
The reduction of BP alone does not eliminate the increased 
risk of arterial hypertension, and the agents that block the 
RAAS theoretically offer additional benefits other than reduc-
tion of BP, but this has been difficult to prove in   practice. 
Candesartan has been used in several key clinical trials of 
hypertension to determine its efficacy, tolerability, and safety 
(Table 1).
BP-lowering efficacy: candesartan  
versus placebo studies
Reif et al18 evaluated the dose-related efficacy, tolerability, 
and safety of candesartan cilexetil in 365 adult patients with 
hypertension; all doses of candesartan cilexetil (2, 4, 8, 16, 
or 32 mg once daily for 8 weeks) reduced trough sitting DBP 
(−7.1, −8.4, −8.7, −7.8, and −10.2 mmHg, respectively) and 
SBP (−8.9, −10.5, −9.9, −10.7, and −12.6 mmHg, respec-
tively) significantly compared with placebo (P , 0.005). 
A significant (P , 0.0001) dose response was evident, with 
greater decreases in BP at higher doses. In a meta-analysis 
that reviewed the antihypertensive activity of several ARBs,19 
candesartan showed significant clinical and 24-hour SBP and 
DBP reductions compared with placebo. Similarly, in the Trial 
of Preventing Hypertension (TROPHY)20 and the Danish 
Hypertension Prevention Project (DHyPP)21 studies, cande-
sartan was more effective than placebo in BP reduction.
Combination therapy studies
The Nifedipine Candesartan Combination (NICE Combi) trial22 
was a 16-week study of 258 patients with essential hyperten-
sion (age range 20–80 years). The trial investigated the changes 
in BP, pulse pressure (PP), and urine albumin-to-creatinine 
ratio (UACR) in these patients randomized to candesartan 
monotherapy or candesartan plus controlled-release nifedipine. 
SBP, DBP, and PP were significantly more reduced in the 
combination therapy group than in the monotherapy group 
(P , 0.0001 for SBP and DBP; P = 0.0031 for PP). UACR 
decreased significantly in the combination therapy group 
(P , 0.05) but not in the monotherapy group.
Another 16-week study23 with the objective of evalu-
ating the efficacy and tolerability of 32 mg candesartan 
cilexetil in combination with 12.5 or 25 mg hydrochloro-
thiazide (HCTZ) in patients with hypertension not opti-
mally controlled with candesartan monotherapy reported 
reduction of BP by 6.1/5.6 mmHg in the 32 mg can-
desartan group (vs 13.0/8.8 mmHg in the 32/12.5 mg Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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candesartan–HCTZ group and 15.5/10.0 mmHg in the 
32/25 mg candesartan–HCTZ group; P , 0.01). Therefore, 
candesartan–HCTZ combination was concluded as effective 
for the treatment of hypertension in patients with hyperten-
sion not optimally controlled with candesartan monotherapy. 
Also, in a smaller study of 25 elderly Japanese hypertensive 
patients with diabetes who received candesartan and add-on 
calcium chanel blocker (CCB) treatment benidipine hydro-
chloride and who were followed up for 4 months, Sasaki 
et al24 showed significant reduction in SBP and DBP after the 
addition of benidipine hydrochloride (from 154/91 to 139/78 
mmHg; P , 0.01).
A large, randomized, double-blind, placebo-controlled 
study of 4,632 patients with mild to moderate hypertension 
used a mathematical model (Emax model) to describe the 
placebo-adjusted dose-response surface for SBP and DBP 
reductions after 8–12 weeks of combination therapy with 
candesartan (2–32 mg) and HCTZ (6.25–25 mg).25   Reduction 
of BP increased with increasing doses of candesartan–HCTZ, 
from 5.9 to 17.4 mmHg for SBP and from 2.8 to 10.2 mmHg 
for DBP. Using this model, it was concluded that the effect 
of combination therapy with candesartan–HCTZ is dose-
related over a wide range of doses and that the effects of the 
components were fully additive.
Comparative efficacy: candesartan versus 
other antihypertensives
A multicenter study that compared the antihypertensive effect 
and tolerability of candesartan cilexetil with those of losartan 
and placebo in patients with essential   hypertension concluded 
that once-daily dose 16 mg of candesartan   cilexetil is signifi-
cantly more effective than 50 mg of losartan.26 In this study, 
8 mg of candesartan was as effective as 50 mg of losartan, 
whereas 16 mg of candesartan cilexetil was significantly more 
effective (P = 0.013). Compared with the placebo treatment, 
trough sitting DBP was significantly reduced by a mean of 
8.9 mmHg (P , 0.001) with 8 mg of candesartan cilexetil and 
10.3 mmHg (P , 0.001) with 16 mg of candesartan cilexetil.
Fabia et al19 conducted a meta-analysis to   systematically 
review the antihypertensive activity of ARBs. In this   analysis, 
47 patient cohorts received ARB in monotherapy, 10 received 
placebo, 10 received amlodipine, and 5 received enalapril. 
The lowering of clinical and ambulatory BP during daytime, 
nighttime, 24-hour period and the last 4-hour period for each 
of the drugs considered were calculated and appropriately 
adjusted for. When only ARBs were evaluated, the drug used 
was a determinant for SBP reduction, whereas for DBP, 
the influence was on the BP reduction and the   duration of 
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the antihypertensive activity. The dose used had a particular 
influence on the duration of the antihypertensive activity for 
both SBP and DBP. Candesartan, telmisartan,   irbesartan, 
and olmesartan all showed similar patterns of SBP and DBP 
reductions.
The antihypertensive efficacy and tolerability of candesar-
tan and amlodipine were evaluated in an 8-week, multicenter, 
  double-blind, randomized, parallel-group, forced-titration 
study (a comparative study of Candesartan and Amlodipine 
for Safety, Tolerability, and Efficacy [CASTLE]).27 A total of 
251 adult patients with mild hypertension were randomized to 
receive 16 mg of candesartan or 5 mg of amlodipine once daily 
(uptitrated to 32 mg of candesartan or 10 mg of amlodipine 
once daily after 4 weeks). There were no significant differ-
ences between the candesartan and the amlodipine regimens 
in   reducing BP as 79% of patients on candesartan and 87% of 
patients on amlodipine were controlled (DBP , 90 mmHg). The 
primary end point (change in trough sitting DBP from baseline 
to week 8) was −10.2 mmHg (−11.6 to −8.9 mmHg) for patients 
in the candesartan group and −11.3 mmHg (−12.6 to −10.0 
mmHg) for patients in the amlodipine group (P = 0.25).
Prevention of hypertension
Several clinical trials, including the TROPHY20 and the DHyPP,21 
have been conducted to evaluate the efficacy of candesartan in 
preventing the occurrence of clinical hypertension in subjects at 
risk compared with placebo. The hypothesis was that angiotensin 
II is a key player in the genesis of hypertension and by blocking 
the RAAS in patients with high-normal BP or those at risk for 
hypertension, it would be prevented in the long term.
The TROPHY trial was a 4-year investigator-initiated 
trial of 809 randomized subjects that examined whether early 
pharmacological treatment in subjects with “high-normal” BP 
might prevent or delay the development of clinical hyperten-
sion. At year 4, there was a relative reduction in the risk of 
new-onset hypertension of 15.6% in participants in the can-
desartan group (P = 0.007).20 The DHyPP study investigated 
whether early treatment with candesartan in young normo-
tensive offspring of hypertensive parents persistently reduced 
BP after withdrawal of treatment. After 12 months of therapy, 
there was reduction in mean ambulatory BP monitoring 
by −3.9/−3.4 mmHg for candesartan versus 0.3/0.6 mmHg for 
placebo (P , 0.0001),21 but after 12 and 24 months of with-
drawal of active treatment, there was no difference.21 Overall, 
although these trials indicate that candesartan can reduce 
BP in persons with prehypertension and persons at risk for 
hypertension, the trials also showed that it does not ultimately 
prevent hypertension but may only delay its onset.
Candesartan: prevention of target 
organ damage
Microalbuminuria
The Candesartan and Lisinopril Microalbuminuria (CALM) 
studies (CALM and CALM II)28,29 were designed to assess 
and compare the effects of candesartan or lisinopril, or both, 
principally on BP and on urinary albumin excretion (CALM) 
in patients with microalbuminuria, hypertension, and type 2 
diabetes. In the CALM study,28 after 12 weeks of treatment, 
both candesartan and lisinopril monotherapies showed equal 
efficacy in DBP and UACR definition reduction. At 24 weeks 
of treatment, mean reduction in DBP with dual therapy (16.3, 
13.6–18.9 mmHg; P , 0.001) was significantly greater than 
that with candesartan (10.4, 7.7–13.1 mmHg; P , 0.001) or 
lisinopril (10.7, 8.0–13.5 mmHg; P , 0.001) alone. Mean 
UACR reduction at 24 weeks of treatment was also signifi-
cantly greater with dual therapy than with candesartan or 
lisinopril alone. The CALM II study29 with longer duration 
of follow-up (12 months) had only 2 arms (40 mg lisinopril 
daily and 20 mg lisinopril daily plus 16 mg candesartan daily) 
and showed no statistically significant difference between 
lisinopril (40 mg once daily) and lisinopril (20 mg) in com-
bination with candesartan (16 mg once daily) in reducing 
both SBP and DBP in hypertensive patients with diabetes. 
Although no significant difference in BP control or reduction 
in albuminuria was seen in the CALM II study, the investiga-
tors suggested that the use of dual blockade would diminish 
the ACE-escape phenomenon while preserving the effect on 
bradykinin degradation from the ACE inhibitor.
The ONTARGET study30 that tested the dual blockade of 
the RAAS in patients at high CV risk also reported slightly 
better control of BP with ARB and an ACE inhibitor in 
combination, but no improvement in CV outcome and more 
adverse events were reported. Progression to microalbu-
minuria was delayed by combination therapy compared with 
monotherapy alone, but glomerular filtration rate was lower 
in the combination group and there were more cases of acute 
renal failure. Currently, dual blockade with an ACE inhibitor 
and an ARB is not generally recommended for prevention of 
microalbuminuria as evidence that dual blockade provides 
additional benefits for renal and CV outcomes is lacking.
Diabetic retinopathy
The DIabetic REtinopathy Candesartan Trials (DIRECT) 
programme,31,32 consisting of 3 separate randomized, double-blind, 
placebo-controlled clinical trials, was designed to assess whether 
candesartan could reduce (1) incidence of retinopathy in type 1 
diabetes (DIRECT-Prevent 1),31 (2)   progression of retinopathy Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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in type 1 diabetes (DIRECT-Protect 1),31 and (3) progression of 
retinopathy in type 2 diabetes (DIRECT-Protect 2) (Table 2).32 In 
the study conducted on patients with type 1 diabetics, incidence 
of retinopathy was 25% in the candesartan group versus 31% 
in the placebo group (P = 0.0508), whereas established retin-
opathy progressed equally (13%) in both groups (P = 0.85).31 
Although by the end of the trial, the results of DIRECT-Protect 
2 showed an overall change toward less severe retinopathy in 
the candesartan group (odds ratio = 1.17; 95% CI, 1.05–1.30, 
P = 0.003), the risk of progression of retinopathy was nonsig-
nificantly reduced by 13% in patients on candesartan compared 
with those on placebo hazard ratio [HR] = 0.87; 95% CI, 
0⋅70–1⋅08, P = 0.20).32
The findings of the DIRECT study are in close   agreement 
with the results of the EUrodiab Controlled trial of   Lisinopril 
in Insulin-dependent Diabetes (EUCLID) study33 (30% 
reduction in incidence of retinopathy), which suggested that 
blockade of the RAAS with the ACE inhibitor, lisinopril, 
could reduce both incidence and progression of retinopathy in 
patients with type 1 diabetes. Therefore, the DIRECT investi-
gators have concluded that candesartan reduces the incidence 
of retinopathy in patients with type 1 diabetes and have 
suggested that treatment with candesartan in type 2 diabetic 
patients with mild to moderate retinopathy could induce 
improvement of retinopathy.
Carotid intima media thickness
The Media Intima Thickness Evaluation with Candesartan 
(MITEC) study34 was a multicenter, randomized, double-
blind, active controlled, and parallel-group study conducted 
in hypertensive patients with type 2 diabetes to evaluate the 
effect of candesartan in the progression of carotid intima 
media thickness (CIMT) over 36 months in comparison 
with amlodipine (Table 2). No significant differences were 
observed between the two groups for change in the progres-
sion of CIMT at 12, 24, and 36 months (P = 0.425, P = 0.442, 
and P = 0.549, respectively). At the last visit, CIMT regres-
sion was observed in 52.2% of patients receiving candesartan 
and in 51.3% of patients receiving amlodipine (P = .908). The 
results of this study, therefore, showed that   candesartan and 
amlodipine change the natural progression of CIMT in similar 
ways in hypertensive patients with type 2 diabetes.
Candesartan: outcome studies
Several studies have shown that ARBs effectively reduce BP. 
However, reduction of BP is only a surrogate end point as 
these studies have also verified the importance of ARBs in 
protecting target organs. ARBs have shown favorable effects 
on hemodynamic measurements, neurohumoral activity, and 
left-ventricular remodeling when added to ACE inhibitors in 
patients with chronic heart failure (CHF).
The Candesartan in Heart failure: Assessment of   Reduction 
in Mortality and Morbidity (CHARM)   programme35–38 
was specifically designed as three parallel, independent, 
  integrated, randomized, double-blind, placebo-controlled, 
clinical trials comparing candesartan with placebo in 
three distinct but complementary populations of patients 
with symptomatic diastolic HF (CHARM-Preserved) or 
  symptomatic systolic HF (CHARM-Added and CHARM-
Alternative). In CHARM-Overall35 study (primary end point: 
all-cause mortality), 7,601 patients with CHF and/or left 
ventricular ejection fraction # 40 or $ 40 were randomly 
assigned to candesartan or placebo therapy group. There 
were fewer deaths (23%) in the candesartan group than in 
the placebo group (25%) (unadjusted HR = 0.91; 95% CI, 
0⋅83–1⋅00, P = 0.055), with fewer CV deaths (unadjusted 
HR = 0.88; 95% CI, 0⋅79–0⋅97, P = 0.012) and hospital 
admissions for CHF (P , 0.0001) in the candesartan group. 
In the CHARM-Added study36 (n = 2,548; primary end point: 
composite of CV death or hospital admission for CHF), 38% 
of patients in the candesartan group and 42% of patients 
in the placebo group experienced the primary   outcome 
(unadjusted HR = 0.85; 95% CI, 0⋅75–0⋅96, P = 0.011), 
and candesartan demonstrated significant reduction of each 
of the   components of the primary outcome, as well as the 
total number of hospital admissions for CHF. The results of 
the CHARM-Preserved37 study conducted in patients with 
preserved left ventricular function showed that CV death did 
not differ between groups (170 vs 170), but fewer patients 
in the candesartan group than in the placebo group were 
admitted one or more times for CHF (230 vs 279; P = 0.017). 
Similarly, the results of the CHARM-Alternative study38 con-
ducted in CHF patients intolerant of ACE inhibitors showed 
that fewer patients in the candesartan group had CV death 
or hospital admission for CHF (unadjusted HR = 0.77; 95% 
CI, 0⋅67–0⋅89; P = 0.0004) and that each component of the 
primary outcome was reduced, as was the total number of 
hospital admissions for CHF.
Other large trials have also tested the effects of cande-
sartan on CV outcomes in different populations. Some of 
these   studies (Randomized Evaluation of Strategies for Left 
Ventricular Dysfunction [RESOLVD], Study on   COgnition 
and Prognosis in the Elderly [SCOPE], Acute   Candesartan 
Cilexetil Therapy in Stroke   Survivors [ACCESS],   Candesartan 
Antihypertensive Survival   Evaluation in Japan [CASE-J], 
Heart Institute of Japan Candesartan Randomized Trial for Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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Evaluation in Coronary Artery Disease [HIJ-CREATE], and 
the Insight of Stent intimal Hyperplasia Inhibition by New 
angiotensin II receptor antagonist trial [ISHIN]39–44 have mostly 
reported favorable results for candesartan when compared with 
placebo or in combination with another agent, but the studies 
have found no difference in CV end points in   comparison with 
other antihypertensive agents. For instance, in the RESOLVD 
pilot study,39 end-diastolic (EDV) and end-systolic (ESV) vol-
umes increased less with   combination therapy (EDV 8 ± 4 mL; 
ESV 1 ± 4 mL; P , 0.01) than with candesartan alone (EDV 
27 ± 4 mL; ESV 18 ± 3 mL) or enalapril alone (EDV 23 ± 7 
mL; ESV 14 ± 6 mL). However, the CASE-J Trial,42 which 
compared the long-term effects of candesartan and amlodipine 
on the incidence of CV events, reported no significant dif-
ferences in CV morbidity or mortality in high-risk Japanese 
patients with   hypertension (HR = 1.01; 95% CI, 0.79–1.28, 
P = 0.969). Also, the HIJ-CREATE43 study designed to test 
whether ARB therapy can reduce the incidence of CV events 
compared with non-ARB-based standard pharmacotherapy in 
coronary artery disease patients with hypertension showed no 
significant differences in first major adverse CV events com-
pared with the non-ARB treatment group: CV death (2.7% vs 
2.4%; HR = 1.14; 95% CI, 0.66–1.95), nonfatal myocardial 
infarction (2.8% vs 2.5%; HR = 1.12; 95% CI, 0.66–1.88), or 
HF (3.9% vs 4.3%; HR = 0.91; 95% CI, 0.59–1.40).
The SCOPE40 was an international outcomes study con-
ducted between 1997 and 2002 in 527 centers in 15 countries 
worldwide. The design was a prospective, double-blind, 
randomized, and parallel-group study, which included 4,964 
patients aged 70–89 years with SBP 160–179 mmHg or DBP 
90–99 mmHg, or both, and with a mini-mental state evaluation 
(MMSE) score of at least 24. Patients were randomly assigned 
to receive 8 mg of candesartan daily or placebo (it was a com-
parison with a control group that received other antihypertensive 
drugs, mostly diuretics). Candesartan-based treatment reduced 
nonfatal stroke by 28% (relative risk [RR] = 0.72; 95% CI, 
0.53–0.99, P = 0.04) and all stroke by 24% (RR = 0.76; 95% CI, 
0.58–1.01, P = 0.056). The events rate for nonfatal stroke was 
7.4 events per 1,000 patient-years compared with 10.3 events 
per 1,000 patient-years for the candesartan and the placebo 
group, respectively. The mean change in MMSE score was not 
significantly different between the treatment groups (candesar-
tan −0.49 and placebo −0.64; P = 0.20), and there was also no 
significant difference in dementia between the treatment groups 
(6.8 events per 1,000 patient-years in the candesartan group and 
6.3 events per 1,000 patient-years in the control group). Finally, 
although the use of candesartan in the CHARM-Overall study35 
did not significantly reduce the risk of stroke (candesartan 
141 and placebo 146; P = 0.63), the significant benefits of 
candesartan treatment were still maintained when a prespecified 
analysis of time to first event was conducted for nonfatal CV 
events, admission to hospital for HF and CV death.
Candesartan: trials with metabolic-
profile-based outcomes
A few trials that have primarily or secondarily assessed the 
metabolic effects of candesartan include the Antihypertensive 
Treatment and Lipid Profile in a North of Sweden Efficacy 
Evaluation (ALPINE) study,45 the Mechanisms for the Dia-
betes Preventing Effect of Candesartan (MEDICA) Study,46 
the HIJ-CREATE,43 and the CASE-J Trial.42
Koh et al47 have published the results of a small, random-
ized, double-blind, placebo-controlled cross-over trial with 3 
treatment arms that sought to clarify whether the combination 
therapy of ramipril and candesartan had additive beneficial 
effects to simultaneously improve the endothelial dysfunction 
and the adipocytokine profiles in patients with hypertension. 
Combination therapy improved these outcome measures to a 
greater extent than did either ramipril or candesartan alone. In 
addition, combination therapy reduced plasma leptin levels to 
a greater extent than did either ramipril or candesartan alone 
(P = 0.042). Change in adiponectin levels showed correla-
tions with: change in the quantitative insulin sensitivity check 
index [QUICKI] (r = 0.319, P = 0.066) following ramipril 
therapy; change in QUICKI (r = 0.374, P = 0.029) following 
combination therapy; and change in QUICKI (r = 0.607, P < 
0.001) following candesartan therapy. QUICKI (r = 0.607; 
P , 0.001) following candesartan therapy. The result from 
this trial suggests that candesartan, alone or in combination 
with ramipril, has vascular benefits by improving endothelial 
dysfunction commonly observed in diabetes, insulin resis-
tance, and other disease states that may be associated with 
impaired nitric oxide release from the endothelium. The 
improvement in endothelial dysfunction is thought to possibly 
occur by targeting the RAAS through different mechanisms 
and by body mass index independent increases in adiponectin 
levels and insulin sensitivity.
The aim of the ALPINE study45 was to compare the 
long-term effect of low-dose HCTZ, alone or in combina-
tion with atenolol (a β-blocker), with that of candesartan, 
alone or in combination with felodipine (a CCB), in newly 
diagnosed patients with primary hypertension. The   objectives 
included comparisons of the effects on glucose and lipopro-
tein metabolism. Fasting serum insulin and fasting plasma 
glucose levels increased in the HCTZ group compared with 
unaffected levels in the candesartan group. Diabetes   mellitus Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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was diagnosed in 4.1% of the HCTZ group (vs 0.5% in the 
candesartan group; P = 0.030). The HCTZ group also had 
higher mean triglyceride with lower mean high-density 
lipoprotein-cholesterol than the candesartan group. At 
12 months, 18 patients in the HCTZ group (vs 5 patients in 
the candesartan group, P = 0.007) had a metabolic syndrome, 
as defined by the World Health Organization.
The favorable metabolic outcomes obtained from other 
studies can be summarized as follows: in the CASE-J study,42 
new-onset diabetes occurred in significantly fewer patients 
treated with candesartan-based regimens than in those treated 
with amlodipine-based regimens; in the HIJ-CREATE 
study,43 new-onset diabetes was diagnosed in fewer of the 
patients assigned to the candesartan-group compared with 
the controls (HR = 0.37; 95% CI, 0.16–0.89; P = 0.03); in 
the MEDICA study,46 visceral fat redistribution, liver fat 
accumulation, low-grade inflammation, and aggravated 
insulin resistance were demonstrated after HCTZ treatment 
but not after candesartan treatment.
Candesartan: safety, tolerability,  
and patient perspectives
Most of the reported trials have included and assessed 
the safety, tolerability, and occurrence of adverse events 
  associated with candesartan. In general, candesartan has 
been reported by these trials to be safe and well tolerated 
by patients and significantly fewer patients have usually 
  discontinued their participation or withdrawn from most trials 
due to adverse events or for safety concerns.
In the CHANCE study,48 once-daily dose of 8–16 mg 
of candesartan was effective and well tolerated in the man-
agement of arterial hypertension in elderly subjects. In the 
MITEC study,34 significantly more adverse events related 
to the study drug occurred in the amlodipine group than in 
the candesartan group (32.1% vs 13.0%; P = 0.001). In the 
HIJ-CREATE study,43 the difference in adverse events was 
found to be driven by cough and anemia in the non-ARB 
group leading to more frequent discontinuation of the study 
drug in the non-ARB-based standard therapy group than in 
the candesartan group (12.2% vs 5.7%; P , 0.001).
However, in the CHARM study,35 even though candesar-
tan was well tolerated by patients, it was associated with a 
greater occurrence of discontinuation of the study drug than 
placebo due to hypotension, hyperkalemia, and increase in 
serum creatinine levels. Also, more cancer deaths occurred in 
the candesartan group, but these deaths were attributed to the 
play of chance since the investigator-reported rate of nonfatal 
neoplasms did not differ among treatment groups. No other 
studies have reported such findings. In all,   candesartan 
appears to be safe and well-tolerated drug.
Conclusions
Candesartan, a long-acting antihypertensive agent, has 
been shown to have a more efficacious antihypertensive 
activity than other ARBs such as losartan, and it effectively 
combines with other antihypertensive agents such as thiaz-
ide diuretics and CCBs to control BP. Several randomized 
  clinical studies have also shown candesartan to be a well-
tolerated drug with favorable metabolic characteristics. 
It reduces microalbuminuria in type 2 diabetics, prevents 
progression of CIMT, and may have positive benefits in 
preventing type 2 diabetic retinopathy. Candesartan reduces 
CV events in patients with HF intolerant to ACE inhibitors 
and in combination with ACE inhibitors in patients with HF 
and reduced ejection fraction. There are suggestive data that 
it may be useful in patients with acute stroke and prevent 
stroke in elderly hypertensives. Candesartan is, therefore, 
an attractive antihypertensive agent with additional benefits 
on target organ damage and both CV and cerebrovascular 
outcomes.
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